Clinical Trials Browser

INDUSTRY × Interventional × talazoparib × Clear all

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03395197 2026-04-07

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04497116 2025-10-21

TRESR

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled 43 charts

Breast Neoplasms, Neoplasms

NCT03148795 2024-04-05

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

128 enrolled 25 charts

Prostatic Neoplasms

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Phase 1/2 Terminated

223 enrolled 50 charts

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04635631 2023-10-10

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Phase 1 Completed

15 enrolled 38 charts

Neoplasms

NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2 Terminated

202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Phase 3 Terminated

79 enrolled 18 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Phase 2 Completed

120 enrolled 16 charts

Neoplasms

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03637491 2022-01-26

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Phase 1/2 Terminated

36 enrolled 22 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01945775 2022-01-20

EMBRACA

Phase 3 Completed

431 enrolled 23 charts 2 FDA

Breast Neoplasms

NCT03499353 2021-11-09

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2 Terminated

61 enrolled 63 charts

Breast Neoplasms

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT03077607 2021-06-30

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

36 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02997176 2021-02-25

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

Phase 1 Completed

38 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02997163 2021-01-05

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

Phase 1 Completed

34 enrolled 39 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03042910 2019-12-17

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

Phase 1 Completed

38 enrolled 24 charts

Other solid neoplasm

Solid Tumor

NCT02034916 2019-10-14

ABRAZO

Phase 2 Terminated

84 enrolled 21 charts

Breast Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT03070548 2018-12-17

A Study of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

6 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn

Ovarian Neoplasms

NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell